Kornimate/medical-research-clean huggingface dataset:
bile usefulness for detecting igg4-related sclerosing cholangitis

Conditions: IgG4-related Sclerosing Cholangitis; IgG4-related Disease

Summary: immunoglobulin g4-related disease (igg4-rd) is an uncommon inflammatory disorder that may affect multiple organ systems, including the biliary tree. igg4-sclerosing cholangitis (igg4-sc) can be difficult to distinguish from primary sclerosing cholangitis (psc) or cholangiocarcinoma (cca). the investigators aim to evaluate the sensitivity and specificity of bile for the diagnosis of igg4-sc. bile samples of patients with biliary strictures of various causes, including igg4-sc, psc, and cca, will be collected during clinical cholangiography procedures. igg4 will be measured in bile specimens and bile igg4 concentrations compared between igg4-sc, psc, cca, and other types of biliary strictures.

this study will recruit cases from mayo clinic rochester and japanese institutions such as nagoya city university hospital, nagoya daini red cross hospital, and kurashiki central hospital. participants will be individuals who will receive endoscopic retrograde cholangiography (erc), endoscopic ultrasound-guided fine-needle aspiration (eus-fna) or percutaneous transhepatic cholangiography (ptc). bile samples collected from the target cases will be assayed for igg4 concentration.

Eligibility criteria:
inclusion criteria: * the presence of a biliary stricture * 18 years and older * consented to irb 707-03 exclusion criteria: * younger than 18 years of age * unable to collect a bile sample * abnormal postsurgical anatomy preventing collection of a bile sample
mk-2060 and clopidogrel co-administration safety and tolerability study in participants with end-stage renal disease (esrd) (mk-2060-008)

Conditions: End-Stage Renal Disease; Kidney Failure, Chronic

Summary: mk-2060 is being developed for prevention of thrombotic complications in end-stage renal disease (esrd). the purpose of this study is to conduct a preliminary evaluation of the safety and tolerability of mk-2060 treatment in combination with a commonly used p2y12 receptor inhibitor, clopidogrel, in esrd patients.


Eligibility criteria:
inclusion criteria: * has end-stage renal disease (esrd) maintained on stable outpatient hemodialysis (hd) regimen at a healthcare center for \> 3 months prior to dosing. * on hd regimen at least 3 times per week for a minimum of 3 hours per dialysis session, using a complication-free well-maintained av fistula or av graft. * is taking clopidogrel for a minimum of 2 weeks prior to the first dosing of mk-2060 administration. * has a body mass index (bmi) ≥ 18 and ≤ 45 kg/m\^2. exclusion criteria: * history of cancer (malignancy), including adenocarcinoma, except adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies that have been successfully treated with appropriate follow up. * has a history of deep vein thrombosis or pulmonary embolism. * has a history of gastrointestinal (gi) bleeding, duodenal polyps or gastric ulcer in the last 5 years or severe hemorrhoidal bleed in last 3 months prior to screening. * is positive for hepatitis b surface antigen or human immunodeficiency virus (hiv). * has ongoing anticoagulant therapy or antiplatelet therapy, not including clopidogrel. intradialytic heparin is permitted.
rectus sheath block and local wound infiltration in pediatric laparoscopic appendectomies

Conditions: Appendectomy, Laparoscopic; Pediatric Anesthesia; Nerve Block/Methods; Regional Anesthesia; Acute Pain, Postoperative

Summary: laparoscopic appendectomy surgeries are among the most commonly performed procedures in childhood. however, they are associated with moderate to severe postoperative pain. regional nerve block techniques are recommended for postoperative pain management. this research compared the two most frequently used methods: rectus sheath block and local wound infiltration.

acute appendectomy surgeries are one of the most frequently performed surgeries in childhood. minimally invasive (laparoscopic) surgical methods are recommended, especially in abdominal surgeries, due to rapid wound healing, rapid recovery, less bleeding, and shorter hospital stays compared to open surgery. in addition to all these advantages of laparoscopic surgeries, postoperative somatic pain is expected to be less compared to open surgeries due to the small incisions in the abdominal wall. however, when the pain severity of children who underwent laparoscopic appendectomy was evaluated using the pain scoring scale, it was seen that the median pain scores were ≥7 in 5% of the children (severe pain) and ≥4 in 25% (moderate pain). clinical practice guidelines also recommend the use of regional anesthesia and analgesia methods as part of multimodal analgesia in the prevention of intraoperative and postoperative pain. we also routinely use regional anesthesia and analgesia methods successfully and effectively in our daily practices in our clinic. rectus sheath blocks, which are known to be effective in midline incisions, and local anesthetic infiltrations of the wound site, which do not require special technical knowledge about regional anesthesia, are routinely applied in our clinic in every case. although both methods provide clinical benefits, it is unknown which one is superior to the other.

Eligibility criteria:
inclusion criteria: * older than 8 years * younger than 18 years * minimal invasive appendectomy (3 port) * consent to participate exclusion criteria: * younger than 8 years * older than 18 years * convert to open abdominal surgery * do not consent to participate

Keywords: laparoscopic appendectomy pediatric anesthesia nerve blocks regional anesthesia acute postoperative pain
effect of dry cupping and ischemic compression on the trigger point on the upper trapezius muscle

Conditions: Trigger Point Pain, Myofascial

Summary: ischemic compression is considered the fastest and most common method for providing relief in trigger point therapy, whereas cupping therapy is not a method often used for this purpose. the muscle that has a great impact on tension-type headaches and neck pain is the trapezius, whose upper fibres are where the most common trigger point in the back is located. the aim of this study was to evaluate and compare the effectiveness of single ischemic compression and single dry cupping therapy on the most common trigger point, on the descending part of the trapezius muscle.


Eligibility criteria:
inclusion criteria: * age 18-30 * student of the józef piłsudski university of physical education in warsaw * written consent to participate in the study exclusion criteria: * past or current injury to the trapezius. * past or current injury of the cervical spine limiting mobility of this segment. * broken skin at the examination site. * cardiological disease and use of blood pressure medication, histamine medication and analgesics * elevated body temperature, illness symptoms and a period of convalescence. * a missed anti-covid procedure before each examination. * inability to find trigger points.

Keywords: ischemic compression cupping algometer trapezius muscle
vitamin d3 supplementation in pediatric ibd: weely vs daily dosing regimens

Conditions: Inflammatory Bowel Disease (IBD)

Summary: the purpose of this prospecitve randomized controlled trial is to compare effectiveness and patient/family adherence of weekly or daily vitamin d-3 dosing regimens in children with inflammatory bowel disease (ibd) who are 25-hydroxyvitamin d \[25(oh)d\] insufficient or deficient. the primary aim of this pilot study is to evaluate the effectiveness of once weekly verses daily d-3 dosing regimens based on the most current ibd supplementation guidelines in improving 25(oh)d levels. a seconary aim is to determine if there is difference in adherence between dosing regimns.


Eligibility criteria:
inclusion criteria: * subjects aged 5 to 17 years with a diagnosis of inflammatory bowel disease, who have a 25(oh)d level below 30 ng/ml within 2 weeks of enrollment * subject/family must be able and willing to take oral medications, complete a 3 day dietary record, and return for 8 week concluding visit or clinicl visit exclusion criteria: * subjects will not be eligible if they are intolerant of vitamin supplementation or any ingredients in the chosen supplment, are unable or unwilling to take oral supplements, or are on specific medical therapy for diminished bone mineral density * children with parathryoid disease, granulomatous disorders or william's syndrome will also be excluded from the study
tenofovir in early pregnancy to prevent mother-to-child transmission of hepatitis b virus

Conditions: Hepatitis B

Summary: mother-to-child transmission (mtct) of hepatitis b virus (hbv) remains the major mode of transmission in most high and intermediate hbv endemic areas, despite existing who immunoprophylaxis recommendations. this immunoprophylaxis regimen, if given optimally, can prevent 75-80% of hbv mtct, but optimal implementation is difficult because it requires administering monovalent hbv vaccine and hepatitis b immunoglobulin (hbig) within 24 hours of birth. due to the barriers of giving hbig, the world health organization (who) states, "...owing to concerns related to supply, safety and cost, the use of hbig is not feasible in most settings." clearly, global control of hbv transmission will require improved mtct prevention. therefore, the investigators hypothesize that treating hbv early in pregnancy will lead to undetectable hbv dna levels at delivery and prevention of mtct of hbv without hbig; a concept that has already been proven with hiv. tenofovir disoproxil fumarate (tdf), an approved anti-hbv drug, is promising to prevent mtct of hbv due to its high potency against hepatitis b and its safety record in pregnant women. a randomized, controlled clinical trial (rct) will be necessary to determine if tdf given to hbv-infected pregnant women early in pregnancy plus vaccine to the newborn can decrease mtct of hbv without hbig. however, before embarking on a rct, several critical knowledge gaps need to be addressed including the ideal timing for tdf initiation. the purpose of this proposal is to address these knowledge gaps.

the investigators hypothesize that anti-hbv therapy given in the late first or early second trimester achieves undetectable hbv dna at delivery in \>=95% of pregnant women with chronic hepatitis b. the one-arm, open-label, interventional study aims: 1, to estimate the time to complete hbv dna suppression (\<100 iu/ml) in 170 hbv dna positive women who start tdf in the late first or early second trimester; and to estimate the proportion of women with hbv dna \<100 iu/ml at delivery. 2, to address potential barriers to and the efficacy of implementing tdf in early pregnancy to prevent mother-to-child transmission of hepatitis b. the investigators will measure potential barriers to acceptability and effectiveness of this intervention: adherence, potential hepatitis b flares in mothers (safety), and the proportion of hepatitis b infections in the offspring at 1 year of age (efficacy).

Eligibility criteria:
inclusion criteria: * pregnant women aged 18 and over * hbsag positive * in the 12th-20th week of pregnancy * willing to take tdf daily during pregnancy * providing written informed consent * plans to deliver at shoklo malaria research unit (smru) * able and willing to comply with study requirements exclusion criteria: * anti-hiv positive * negative qualitative hbv dna if hbeag negative * on immunosuppressive therapy * elevated creatinine * history of kidney disease * short cervix * history of pregnancy complications or prior pre-term labor

Keywords: mother to child transmission hepatitis b tenofovir
effectiveness of the defocus incorporated spectacle lenses on fast progressing myope - auxiliary group

Conditions: Myopia

Summary: the purpose of this study is to examine the efficacy and performance of the defocus incorporated multiple segments (dims) spectacle lenses on controlling myopia progression in fast progressing myopic children.

dims spectacle lens is a multifocal spectacle lens that produces myopic defocus images and corrects distance refractive errors at the same time. participants will be prescribed a pair of dims spectacle lenses. their cycloplegic refraction and axial length will be monitored every 6 months over 2 years.

Eligibility criteria:
inclusion criteria: * ser: -1.00d or below * documented history of fast progressing myopia, either in ser or al * ser progression: 0.50d/year or more * al elongation: 0.27mm/year or more * best-corrected monocular visual acuity (va) in both eyes: 0.00 logmar (equivalent) or better * acceptance of random group allocation and the masked study design * anisometropia of 1.50 d or less * astigmatism of 2.00 d or less exclusion criteria: * strabismus and binocular vision abnormalities * ocular and systemic abnormalities * prior experience of myopia control

Keywords: myopia defocus
postoperative nausea and vomiting after laparoscopic cholecystectomy

Conditions: Postoperative Nausea; Postoperative Vomiting

Summary: in the present study, midazolam and palonosetron in combination were more effective than palonosetron alone in lowering the incidence and severity of postoperative nausea and vomiting in the initial 2 h after laparoscopic cholecystectomy. postoperative clinical complications were not different in both groups.


Eligibility criteria:
inclusion criteria: * the patients (aged 20 to 65 years) scheduled for laparoscopic cholecystectomy with american society of anesthesiologists (asa) physical status classification of 1 or 2 exclusion criteria: * the patients with a history of allergy to any other drugs used in this study, gastrointestinal disorder, previous ponv, pregnant woman, breastfeeding woman, use of antiemetics within 24 hours or body mass index \> 30 kg/m2

Keywords: postoperative nausea and vomiting midazolam palonosetron
mainz epilepsy registry

Conditions: Epilepsy; Dissociative Seizures; Status Epilepticus

Summary: prospective longitudinal observational registry study of all patients with epilepsy treated in the mainz comprehensive epilepsy and sleep medicine center with the focus on the course of the disease and quality of life.

clinical parameters of patients, such as onset of the disease, prior medication, disease severity, which are important for the data analysis also collected retrospectively before the initiation of the registry. data on the quality of life is collected only prospectively.

Eligibility criteria:
inclusion criteria: * epileptic or psychogenic seizures exclusion criteria: * age\<18 * patients who cannot provide informed consent and don't have a legal guardian
nasopharyngeal bacterial carriage and antibiotic resistance in children with sickle cell disease in ile-de-france

Conditions: Sickle Cell Disease

Summary: the objective of this study is to to determine the rate of nasopharyngeal carriage of streptococcus pneumoniae (sp) in children with sickle cell disease over 6 months and under 15 years of age over a 9-month period in ile-de-france.

sickle cell disease is the most common genetic disease in france, with one affected child for every 1,736 births. ile-de-france is the region in europe with the highest prevalence of sickle cell disease. children with sickle cell disease have an increased susceptibility to infections related to encapsulated bacteria and are at high risk of invasive infections (particularly streptococcus pneumoniae), which is the leading cause of mortality in children with sickle cell disease under 5 years of age worldwide. the patients are subject to intense selection pressure (long-term antibiotic prophylaxis and systematic probabilistic curative antibiotic therapy) and are at high risk of carrying nosocomial bacteria (repeated hospitalizations). moreover, children with sickle cell disease have reinforced immunization schedules, especially against pneumococcal disease. however, data concerning the carriage of resistant bacteria (prevalence, risk factors) in children with sickle cell disease in france are scarce. this study aims to determine the nasopharyngeal bacterial carriage and antibiotic resistance in children with sickle cell disease in ile-de-france

Eligibility criteria:
inclusion criteria: * children aged 6 months to 15 years, regardless of immunization status. * child with a major sickle cell syndrome (ss, sc, s+, s°, se) followed in one of the centers of competence or reference for rare diseases (crmr) " major sickle cell syndromes, thalassemias and other rare pathologies of the red blood cell and erythropoiesis " in ile de france. * children who are not subject to legal protection measures. * child affiliated to a social security system. * signed informed consent exclusion criteria: * sickle cell child with a febrile syndrome at the time of sampling or hospitalized for any reason. * child having received antibiotic therapy other than oracillin in the 7 days preceding the nasopharyngeal swab. * child already included in the observation period (only 1 nasopharyngeal swab per patient). * other hemoglobinopathies and heterozygous as or ac patients. * patients already involved in a therapeutic protocol or in the exclusion period following a previous research. * patients under ame or without social security coverage.

Keywords: sickle celle disease, nasopharyngeal bacterial carriage
glp-1 receptors in normal skin and skin from patients with psoriasis

Conditions: Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI

Summary: to examine glp-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease


Eligibility criteria:
4.3 inclusion criteria * caucasians above 18 years of age * plaque psoriasis * pasi score \>10 * no treatment or stable treatment of psoriasis during at least 3 months before inclusion * steady weight through 3 months with a body mass index (bmi) above 27 kg/m2 * normal blood pressure * spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (\~5 times the plasma half-life) 4.4 exclusion criteria * psoriasis arthritis * fasting plasma glucose \> 7.5 mmol/l or hba1c \> 7.5% * type 1 diabetes * treatment for type 2 diabetes with glp-1-based medicine (ddp-4-inhibitors or glp-1-receptor-agonists) * heart failure, nyha class iii-iv * uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine \>150 µm and/or albuminuria * liver disease (alanine amino transferase (alat) and/or aspartate amino transferase (asat) \>2 x upper normal serum levels) * anaemia * acute or chronic pancreatitis * struma or thyroid cancer * pregnancy or breast feeding * inability to complete the study
helps study - a study of peginterferon alfa-2a (pegasys) in patients with chronic hepatitis c (chc) and end-stage renal disease (esrd)

Conditions: Hepatitis C, Chronic

Summary: this study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with chronic hepatitis c (chc) who have end-stage renal disease (esrd) and were undergoing hemodialysis.


Eligibility criteria:
inclusion criteria: * serum hepatitis c virus ribonucleic acid (hcv rna) quantifiable at greater than (\>) 600 iu/ml * liver biopsy consistent with chronic hepatitis c infection obtained within 2 years of enrollment * compensated liver disease without cirrhosis * participants with end-stage renal disease undergoing hemodialysis * negative serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug * all fertile participants must have been using effective contraception during treatment with study drug exclusion criteria: * interferon therapy at any previous time * liver cirrhosis * signs and symptoms of hepatocellular carcinoma * history or other evidence of decompensated liver disease * any investigational drug less than or equal to 6 weeks prior to the first dose of study drug * history or other evidence of a medical condition associated with chronic liver disease other than hcv (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures) * poorly controlled diabetes * thyroid dysfunction not adequately controlled * evidence of severe retinopathy or clinically relevant ophthalmological disorder * severe hyperparathyroidism defined as intact parathyroid hormone (pth) \> 800 picogram/milliliter (pg/ml) * therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment ≤ 6 months prior to the first dose of study drug * acute renal failure * women with ongoing pregnancy or breast feeding * positive test at screening for anti-hav igm ab (hepatitis a virus immunoglobulin m antibody), hepatitis b surface antigen (hbsag), anti-hbc (hepatitis b core) igm ab, anti-hiv (human immunodeficiency virus) ab
trial of compassionate use of hp802-247 to treat venous leg ulcers in subjects who have failed multiple other healing technologies

Conditions: Venous Leg Ulcer

Summary: compound hp802-247 comprises two topical sprays, administered sequentially right after another; these deliver a suspension of fibroblasts and keratinocytes to the wound surface. hp802-247 is the subject of a larger phase 2 multi-center trial for treating venous leg ulcers. the present study will enroll up to five patients who are suffering venous leg ulcers, have failed a prolonged course of standard wound therapy and one or more advanced technologies, but who would not qualify for the phase 2 study.


Eligibility criteria:
inclusion criteria: * chronic (duration greater than six months) open wound that has been diagnosed as a venous leg ulcer on the basis of consultation with a vascular surgeon and/or venous ultrasound evaluation * patient has been under continuous care at the overlook hospital wound healing program for at least four months for treatment of the study lesion(s) * total study wound surface area greater than or equal to 12 cm2, but less than 48 cm2 * wounds must have failed to heal despite the patient's compliance with elevation, compression and regular debridement, as well as at least one advanced wound therapy (for example, bioengineered dressing such as oasis® or matristem®, low-frequency ultrasound, or cultured skin substitute (apligraf®, dermagraft®) * patient has no reasonable likelihood of healing with additional attempts to treat with fda-approved products and treatments exclusion criteria: * patients eligible to participate in a healthpoint sponsored clinical study of hp802-247 trial (ind 13,900) * patients who have been previously treated with hp802-247 * women of child-bearing potential * patients who are allergic to any of the components of hp802-247
68ga-ni-fapi pet/ct: first-in-human study

Conditions: Malignant Neoplasm

Summary: 68ga-ni-fapi is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (ni)-moiety and a fap-targeting. in this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68ga-ni-fapi pet/ct in patients with different types of cancer.

carcinoma-associated fibroblasts (cafs) are an integral part of the tumor microenvironment, and fibroblast activation protein (fap), as a specific marker of cafs, is overexpressed in more than 90% of epithelial malignant tumors' cafs, with limited expression in normal tissues, making it an appropriate target for various tumors. currently, several tracers targeting fap for diagnostic purposes have been developed, such as 68ga-fapi-04, 68ga-fapi-02, and showed high efficacy in tumor staging and restaging. 68ga-ni-fapi is a novel agent incorporating a hypoxia sensitive nitroimidazole (ni)-moiety and a fap-targeting. this pilot study was prospectively designed to evaluate the safety, biodistribution, radiation dosimetry and diagnostic value of 68ga-ni-fapi in patients with different types of cancer.

Eligibility criteria:
inclusion criteria: * various solid tumors with available histopathological findings * signed informed consent exclusion criteria: * pregnant or lactational women * who suffered from severe hepatic and renal insufficiency